Immuneering Reaffirms First-Line Pancreatic Cancer Focus Following FDA Nod For Rasonque

Immuneering (IMRX) issued a statement emphasizing its strategy in first-line metastatic pancreatic cancer after the FDA approved Revolution Medicines’ (RVMD) Rasonque (daraxonrasib) for previously treated patients. The update is directional but does not provide quantitative results or near-term financial implications, suggesting limited immediate market impact.